Telomir Pharmaceuticals (TELO) said Thursday that a preclinical study showed "significant" age reversal effects in subjects treated with Telomir-1, a compound designed to reverse aging and support longevity.
Among the effects were increased lifespan, improved mobility, and a measurable reversal of biological age markers, according to Telomir.
The company said it is collaborating with the Progeria Foundation to evaluate the effects of Telomir-1 on human progeria cell lines to advance the development of the compound as a potential treatment for children with progeria, a genetic disorder that causes accelerated aging.
Shares of Telomir Pharmaceuticals rose more than 12% in early trading Thursday.
Price: 4.74, Change: +0.54, Percent Change: +12.86
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。